Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Heguang Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1459-5546; OpenAlex author ID A5055508259. Sources: OpenAlex.

Their work

Papers
31 (first author 0, last author 17)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 5 papers · 2021: 2 papers · 2022: 2 papers · 2023: 5 papers · 2024: 4 papers · 2025: 3 papers

Papers 31

  1. Identification of prognostic and therapeutic biomarkers associated with macrophage and lipid metabolism in pancreatic cancer. Co-author DOI 10.1038/s41598-025-99144-z↗
  2. An exploratory study of serum creatine kinase as a prognostic marker for patients with resectable pancreatic cancer: looking into the relationship with body co… Co-author DOI 10.1186/s12937-025-01084-x↗
  3. Metabolic, transcriptomic, and proteomic adaptations in pancreatic ductal adenocarcinoma-patient derived xenograft models across serial passages. Co-author DOI 10.1186/s12967-025-06787-7↗
  4. Pirfenidone antagonizes TGF-β1-mediated gabapentin resistance via reversal of desmoplasia and the 'cold' microenvironment in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217287↗
  5. Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction. Last author DOI 10.1038/s41598-024-56737-4↗
  6. Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway. Co-author DOI 10.1136/jitc-2024-009318↗
  7. Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor. Last author DOI 10.1186/s12885-024-12193-x↗
  8. The cellular trajectories of tumor-associated macrophages decipher the heterogeneity of pancreatic cancer. Co-author DOI 10.1007/s10142-023-01266-y↗
  9. The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer. Co-author DOI 10.1186/s12885-023-11346-8↗
  10. A high serum creatine kinase (CK)-MB-to-total-CK ratio in patients with pancreatic cancer: a novel application of a traditional marker in predicting malignancy… Co-author DOI 10.1186/s12957-023-02903-3↗
  11. High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fendo.2023.1181538↗
  12. Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer. Co-author DOI 10.3389/fphar.2023.1193791↗
  13. Metabolomic analyses redefine the biological classification of pancreatic cancer and correlate with clinical outcomes. Last author DOI 10.1002/ijc.34208↗
  14. Prognostic value of preoperative enhanced computed tomography as a quantitative imaging biomarker in pancreatic cancer. Last author DOI 10.3748/wjg.v28.i22.2468↗
  15. Laparoscopic biopsy and staging for locally advanced pancreatic cancer: experiences of 76 consecutive patients in a single institution. Last author DOI 10.1007/s00423-021-02199-5↗
  16. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer. Last author DOI 10.1007/s00432-020-03463-9↗
  17. Understanding metabolomic characteristics of pancreatic ductal adenocarcinoma by HR-MAS NMR detection of pancreatic tissues. Last author DOI 10.1016/j.jpba.2020.113546↗
  18. High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer. Last author DOI 10.1038/s41419-020-02787-1↗
  19. Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma Last author DOI 10.1097/jp9.0000000000000055↗
  20. Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective,… Co-author DOI 10.1136/bmjopen-2020-039900↗
  21. Overall survival in patients with metastatic pancreatic cancer after surgically primary tumor resected: a SEER-based nomogram analysis Last author DOI 10.21203/rs.2.23955/v1↗
  22. Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. Last author DOI 10.1080/2162402x.2019.1581529↗
  23. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Last author DOI 10.1186/s13045-019-0822-6↗
  24. WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC. Last author DOI 10.1186/s13046-018-0848-6↗
  25. Non-invasively predicting differentiation of pancreatic cancer through comparative serum metabonomic profiling. Last author DOI 10.1186/s12885-017-3703-9↗
  26. Identification and causes of metabonomic difference between orthotopic and subcutaneous xenograft of pancreatic cancer. Last author DOI 10.18632/oncotarget.18057↗
  27. Metabonomic alterations from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma facilitate the identification of biomarkers in serum for … Co-author DOI 10.1039/c6mb00381h↗
  28. Metabonomic changes from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma in tissues from rats. Last author DOI 10.1111/cas.12939↗
  29. Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression. Co-author DOI 10.3892/or.2014.3599↗
  30. PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug. Co-author DOI 10.1097/mpa.0000000000000087↗
  31. Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-β signalling pathway. Co-author DOI 10.1016/s1734-1140(13)71046-6↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianchao Lin · 18 shared papers, 2016–2025 · strength 2.52
  2. Yu Pan · 13 shared papers, 2018–2025 · strength 2.10
  3. Fengchun Lu · 13 shared papers, 2018–2025 · strength 2.10
  4. Jianghua Feng · 9 shared papers, 2016–2025 · strength 1.28
  5. Tianhong Teng · 6 shared papers, 2020–2025 · strength 1.22
  6. Wen Shi · 9 shared papers, 2016–2025 · strength 1.22
  7. Ronggui Lin · 6 shared papers, 2020–2025 · strength 1.14
  8. Zelin Hou · 6 shared papers, 2019–2024 · strength 0.86
  9. Congfei Wang · 7 shared papers, 2013–2025 · strength 0.85
  10. Jiajing Lin · 4 shared papers, 2023–2024 · strength 0.79
  11. Pengfei Guo · 4 shared papers, 2020–2025 · strength 0.77
  12. Qinglin Fei · 5 shared papers, 2019–2021 · strength 0.53
  13. Cong Chen · 2 shared papers, 2023–2025 · strength 0.48
  14. Jin Zhang · 2 shared papers, 2024 · strength 0.45
  15. Minggui Pan · 4 shared papers, 2018–2023 · strength 0.44
  16. Bohan Zhan · 4 shared papers, 2016–2024 · strength 0.44
  17. Jianfeng Gao · 2 shared papers, 2022–2023 · strength 0.35
  18. Lili Wu · 1 shared paper, 2025 · strength 0.30
  19. Maoen Pan · 2 shared papers, 2018–2020 · strength 0.25
  20. Xin Luo · 1 shared paper, 2023 · strength 0.19
  21. Binbin Wei · 1 shared paper, 2022 · strength 0.17
  22. Jieming Xie · 3 shared papers, 2013–2015 · strength 0.15
  23. Sanxi Wang · 1 shared paper, 2020 · strength 0.13
  24. Rong Zheng · 1 shared paper, 2020 · strength 0.12
  25. Xiaobo Li · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.